Brian Klein, Ph.D.

Dr. Klein is a Program Director for the Epilepsy Therapy Screening Program (ETSP) in the Division of Translational Research at NINDS.  He also manages a preclinical epilepsy grant portfolio in the Divison of Neuroscience at NINDS.  Prior to joining NINDS in 2015, Dr. Klein served as a Program Director at the National Cancer Institute (NCI) responsible for preclinical evaluation of agents enrolled in the PREVENT Cancer Drug Development Program. Dr. Klein previously held industry positions at Johnson & Johnson Pharmaceutical Research & Development as the preclinical pharmacologist on three antiepileptic drug development programs, at Neuroadjuvants Inc. directing the preclinical development of modified neuropeptides for epilepsy and pain, and at Cognetix Inc. identifying novel venom-based peptide therapies. Dr. Klein received a Ph.D. in Pharmacology and Toxicology from the University of Utah where his research characterized mouse seizure models utilized by the Anticonvulsant Drug Development Program.